Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene Prices Psoriatic Arthritis Drug Otezla At A Discount, But Higher Than Expected

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s approval of oral apremilast paves the way for the company to establish itself in a range of inflammatory conditions.


Related Content

Earnings Briefs: Biogen, Celgene, Actelion, Cubist
On A Roll With Otezla: Can New Orals And Injectables Crack Psoriasis?
Celgene Makes A Play For Inflammation & Immunology Stake With Apremilast


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts